Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9715MR)

This product GTTS-WQ9715MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9715MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11620MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ6684MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ7314MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ7079MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ1670MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ465MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ14240MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ7570MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW